BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31851779)

  • 1. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells.
    Ge L; Wang H; Xu X; Zhou Z; He J; Peng W; Du F; Zhang Y; Gong A; Xu M
    J Cell Mol Med; 2020 Jan; 24(2):1969-1979. PubMed ID: 31851779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades.
    Yan Y; Zhao P; Wang Z; Liu Z; Wang Z; Zhang J; Ding Y; Hua X; Yu L
    Aging (Albany NY); 2021 Jan; 13(3):4468-4481. PubMed ID: 33495409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
    Chung J; Karkhanis V; Baiocchi RA; Sif S
    J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.
    Huang J; Zheng Y; Zheng X; Qian B; Yin Q; Lu J; Lei H
    Cell Transplant; 2021; 30():9636897211001772. PubMed ID: 33829865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/β-catenin signaling.
    Hu W; Wang Z; Zhang S; Lu X; Wu J; Yu K; Ji A; Lu W; Wang Z; Wu J; Jiang C
    Sci Rep; 2019 May; 9(1):7539. PubMed ID: 31101875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/β-catenin signaling pathway.
    Douchi D; Ohtsuka H; Ariake K; Masuda K; Kawasaki S; Kawaguchi K; Fukase K; Oikawa M; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M
    Cancer Lett; 2015 Aug; 365(1):132-40. PubMed ID: 26047573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
    Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
    Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRMT5/FGFR3/AKT Signaling Axis Facilitates Lung Cancer Cell Metastasis.
    Zheng Y; Lu J; Hu X; Hu X; Gao X; Zhou J
    Technol Cancer Res Treat; 2023; 22():15330338231161139. PubMed ID: 36927233
    [No Abstract]   [Full Text] [Related]  

  • 10. Vimentin loss promotes cancer proliferation through up-regulating Rictor/AKT/β-catenin signaling pathway.
    Ding Y; Lv C; Zhou Y; Zhang H; Zhao L; Xu Y; Fan X
    Exp Cell Res; 2021 Aug; 405(1):112666. PubMed ID: 34052237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
    Li L; Zhang S; Li H; Chou H
    BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein arginine methyltransferase 1 coordinates the epithelial-mesenchymal transition/proliferation dichotomy in gastric cancer cells.
    Zhang Y; Wang D; Zhang M; Wei H; Lu Y; Sun Y; Zhou M; Gu S; Feng W; Wang H; Zeng J; Gong A; Xu M
    Exp Cell Res; 2018 Jan; 362(1):43-50. PubMed ID: 29097184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
    Zhou X; Hu Y; Dai L; Wang Y; Zhou J; Wang W; Di W; Qiu L
    PLoS One; 2014; 9(5):e96718. PubMed ID: 24816687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway.
    Zhu K; Peng Y; Hu J; Zhan H; Yang L; Gao Q; Jia H; Luo R; Dai Z; Tang Z; Fan J; Zhou J
    Carcinogenesis; 2020 Apr; 41(2):130-138. PubMed ID: 31498866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21-Activated kinase 3 promotes cancer stem cell phenotypes through activating the Akt-GSK3β-β-catenin signaling pathway in pancreatic cancer cells.
    Wu HY; Yang MC; Ding LY; Chen CS; Chu PC
    Cancer Lett; 2019 Aug; 456():13-22. PubMed ID: 31051214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.
    Gao F; Alwhaibi A; Sabbineni H; Verma A; Eldahshan W; Somanath PR
    Cancer Lett; 2017 Aug; 402():177-189. PubMed ID: 28602980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERas regulates cell proliferation and epithelial-mesenchymal transition by affecting Erk/Akt signaling pathway in pancreatic cancer.
    Liu Y; Qin P; Wu R; Du L; Li F
    Hum Cell; 2020 Oct; 33(4):1186-1196. PubMed ID: 32700262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
    Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
    Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway.
    Xu Q; Ma J; Lei J; Duan W; Sheng L; Chen X; Hu A; Wang Z; Wu Z; Wu E; Ma Q; Li X
    Biomed Res Int; 2014; 2014():546353. PubMed ID: 24812621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
    Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
    Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.